IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON
IRLAB’s clinical Phase IIb/III study with the drug candidate mesdopetam (IRL790) in development for the treatment of levodopa induced dyskinesia (LIDs) in Parkinson’s disease, will have a study design with the following main points: · Approximately 140 patients evenly distributed across four groups: three dose levels of mesdopetam and one placebo group and a three-month study duration. · The planned primary outcome measure is change in daily hours of ON-time without troublesome dyskinesia as assessed with 24-hour patient home diaries. · The study is planned to be conducted at